NCT06893380View on ClinicalTrials.gov

Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer

RecruitingOBSERVATIONAL
Enrollment

61

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

May 8, 2026

Study Completion Date

December 31, 2026

Conditions
Locally Advanced Biliary Tract CancersMetastatic Biliary Tract Cancers
Interventions
DRUG

Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab.

Tislelizumab: IV 200mg on Day 1 of every 3-week cycle Nab-paclitaxel: IV 75mg/m2 on Days 1 and 8 of every 3-week cycle (up to 16 cycles) Gemcitabine: IV 800mg/m2 on Days 1 and 8 of every 3-week cycle Cisplatin: IV 25mg/m2 on Days 1 and 8 of every 3-week cycle (up to 8 cycles)

Trial Locations (1)

13496

RECRUITING

CHA Bundang Medical Center, Seongnam-si

All Listed Sponsors
lead

CHA University

OTHER